174 related articles for article (PubMed ID: 37765334)
1. Effect of the Similarity of Formulations and Excipients of Approved Generic Drug Products on In Vivo Bioequivalence for Putative Biopharmaceutics Classification System Class III Drugs.
Ren P; Chan T; Yang WC; Frost M; Wang Y; Luke M; Kim MJ; Lionberger R; Zhang Y
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765334
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
3. Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help.
Wu F; Cristofoletti R; Zhao L; Rostami-Hodjegan A
Biopharm Drug Dispos; 2021 Apr; 42(4):118-127. PubMed ID: 33759204
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs.
Ono A; Kurihara R; Terada K; Sugano K
Chem Pharm Bull (Tokyo); 2023; 71(3):213-219. PubMed ID: 36858526
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Excipient Risk in BCS Class I and III Biowaivers.
Metry M; Polli JE
AAPS J; 2022 Jan; 24(1):20. PubMed ID: 34988701
[TBL] [Abstract][Full Text] [Related]
6. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride.
Metry M; Shu Y; Abrahamsson B; Cristofoletti R; Dressman JB; Groot DW; Parr A; Langguth P; Shah VP; Tajiri T; Mehta MU; Polli JE
J Pharm Sci; 2021 Apr; 110(4):1513-1526. PubMed ID: 33450218
[TBL] [Abstract][Full Text] [Related]
7. Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses.
Chow EC; Talattof A; Tsakalozou E; Fan J; Zhao L; Zhang X
AAPS J; 2016 Nov; 18(6):1500-1511. PubMed ID: 27520379
[TBL] [Abstract][Full Text] [Related]
8. A Physiologically Based Pharmacokinetic Model for Studying the Biowaiver Risk of Biopharmaceutics Classification System Class I Drugs With Rapid Elimination: Dexketoprofen Trometamol Case Study.
Zhang X; Ye X; Hu K; Li W; Li W; Xiao Q; Chen L; Yang J
Front Pharmacol; 2022; 13():808456. PubMed ID: 35273497
[TBL] [Abstract][Full Text] [Related]
9. Novel insights into excipient effects on the biopharmaceutics of APIs from different BCS classes: Lactose in solid oral dosage forms.
Kubbinga M; Moghani L; Langguth P
Eur J Pharm Sci; 2014 Sep; 61():27-31. PubMed ID: 24732384
[TBL] [Abstract][Full Text] [Related]
10. Possibility of extending biopharmaceutics classification system based biowaiver to BCS class IIa drug.
Khalid F; Hassan SMF; Noor R; Zaheer K; Hassan F
Pak J Pharm Sci; 2019 Sep; 32(5):2065-2073. PubMed ID: 31813872
[TBL] [Abstract][Full Text] [Related]
11. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
[TBL] [Abstract][Full Text] [Related]
12. Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs.
Flanagan T
Eur J Pharm Biopharm; 2019 Aug; 141():130-138. PubMed ID: 31128247
[TBL] [Abstract][Full Text] [Related]
13. Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA.
Nair AK; Anand O; Chun N; Conner DP; Mehta MU; Nhu DT; Polli JE; Yu LX; Davit BM
AAPS J; 2012 Dec; 14(4):664-6. PubMed ID: 22718306
[TBL] [Abstract][Full Text] [Related]
14. Biowaiver Monograph for Immediate-Release Dosage Forms: Levamisole Hydrochloride.
Kambayashi A; de Meijer M; Wegman K; van Veldhuizen C; Abrahamsson B; Cristofoletti R; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Dressman J
J Pharm Sci; 2023 Mar; 112(3):634-639. PubMed ID: 36563854
[TBL] [Abstract][Full Text] [Related]
15. Investigation to Explain Bioequivalence Failure in Pravastatin Immediate-Release Products.
Ruiz-Picazo A; Colón-Useche S; Perez-Amorós B; González-Álvarez M; Molina-Martínez I; González-Álvarez I; García-Arieta A; Bermejo M
Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31835294
[TBL] [Abstract][Full Text] [Related]
16. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug.
Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A
Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948
[TBL] [Abstract][Full Text] [Related]
17. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
18. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.
Plöger GF; Quizon PM; Abrahamsson B; Cristofoletti R; Groot DW; Parr A; Langguth P; Polli JE; Shah VP; Tajiri T; Mehta MU; Dressman J
J Pharm Sci; 2020 Jun; 109(6):1846-1862. PubMed ID: 32240696
[TBL] [Abstract][Full Text] [Related]
19. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
20. Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir.
Vaithianathan S; Haidar SH; Zhang X; Jiang W; Avon C; Dowling TC; Shao C; Kane M; Hoag SW; Flasar MH; Ting TY; Polli JE
J Pharm Sci; 2016 Feb; 105(2):996-1005. PubMed ID: 26375604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
